Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Eli Lilly And Co (LLY) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs Eli Lilly And Co — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.81, while Eli Lilly And Co trades at $1,221.78 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals.

BOILLLY
Sector
Leveraged / InverseHealth
52-Week High
$87.24$1.24K
52-Week Low
$18.74$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $20.91, up 0.97% with a bearish technical signal as moving averages indicate selling pressure. The stock recently underwent a 1:2 split effective May 28, 2026. Natural gas market volatility and weather-driven demand fluctuations create trading opportunities, though financial fundamentals remain undisclosed in current data.

Outlook hinges on natural gas price movements and energy sector dynamics. Investment appeal lies in leveraged exposure to gas futures via the ETF structure, but risks include commodity price swings and lack of traditional corporate fundamentals. Bearish technicals suggest cautious entry points near support at $20.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY